Docs back anemia meds with new advice

The tug-of-war over anemia drugs rages on. Now, cancer specialists say there's no clinical data to support Medicare's restrictions on the drugs, made by Amgen and Johnson & Johnson.

The American Society of Clinical Oncologists and the American Society of Hematology have banded together to issue their own recommendations for use of Aranesp, Epogen, and Procrit. Based on a three-year review of clinical trials, the recommendations warn of heart risks but advise that patients can safely use higher doses than Medicare now will pay for.

Meanwhile, Sen. Max Baucus of Montana says he'll introduce a resolution to nullify Medicare's new reimbursement policies limiting the anemia drugs.

- take a look at the announcement from ASCO
- here's the Los Angeles Times article

Related Articles:
Aetna restricts use of anemia drugs. Report
FDA backs Medicare's anemia drug limits. Report
Medicare cap on anemia drugs could hammer Amgen. Report
Amgen, J&J win a round in anemia controversy. Report
New rules limit use of anemia drugs. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.